Effet de l'obésité sur la pharmacocinétique de l'énoxaparine (Lovenox - Clexane )

PARIS-BIUP (751062107) / SudocSudocFranceF

Field Dependence of Magnetic Disorder in Nanoparticles

The performance characteristics of magnetic nanoparticles toward application, e.g., in medicine and imaging or as sensors, are directly determined by their magnetization relaxation and total magnetic moment. In the commonly assumed picture, nanoparticles have a constant overall magnetic moment originating from the magnetization of the single-domain particle core surrounded by a surface region hosting spin disorder. In contrast, this work demonstrates the significant increase of the magnetic moment of ferrite nanoparticles with an applied magnetic field. At low magnetic field, the homogeneously magnetized particle core initially coincides in size with the structurally coherent grain of 12.8(2) nm diameter, indicating a strong coupling between magnetic and structural disorder. Applied magnetic fields gradually polarize the uncorrelated, disordered surface spins, resulting in a magnetic volume more than 20% larger than the structurally coherent core. The intraparticle magnetic disorder energy increases sharply toward the defect-rich surface as established by the field dependence of the magnetization distribution. In consequence, these findings illustrate how the nanoparticle magnetization overcomes structural surface disorder. This new concept of intraparticle magnetization is deployable to other magnetic nanoparticle systems, where the in-depth knowledge of spin disorder and associated magnetic anisotropies are decisive for a rational nanomaterials design

Correction: Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial.

[This corrects the article DOI: 10.1371/journal.pone.0158235.]

Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial.

TRIAL REGISTRATION ClinicalTrials.gov NCT01341431

Baseline characteristics in the placebo / bee venom groups.

<p>Baseline characteristics in the placebo / bee venom groups.</p

Main results in the placebo / bee venom groups.

<p>Main results in the placebo / bee venom groups.</p

Kinetics of bee venom specific antibodies.

<p>The sample at day -60 was taken at the pre-screening, the first bee venom injection was done at day 0 and the first sample after at day 30. Diamonds are for specific IgE (kU/L) and the squares for specific IgG4 (mg/L). (A)kinetics of specific IgE production for all patients; (B) kinetics for specific IgE and IgG4 for a single representative patient.</p

Study Flowchart.

<p>Study Flowchart.</p

Bee Venom for the Treatment of Parkinson Disease – A Randomized Controlled Clinical Trial - Fig 2

<p>Evolution of the differences of UPDRS III (A), II (B) and total scores (C) with baseline over the 11 month study period in the placebo and bee venom groups.</p

Comparison of [123I]-FP-CIT binding potential changes between V2 and V13 in the placebo / bee venom groups.

<p>Comparison of [123I]-FP-CIT binding potential changes between V2 and V13 in the placebo / bee venom groups.</p